scholarly journals Extraction and structural analysis of Angelica sinensis polysaccharide with low molecular weight and its lipid‐lowering effect on nonalcoholic fatty liver disease

2020 ◽  
Vol 8 (7) ◽  
pp. 3212-3224
Author(s):  
Ping Ma ◽  
Congyong Sun ◽  
Wenjing Li ◽  
Wenwen Deng ◽  
Michael Adu‐Frimpong ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Liver Disease ◽  
Structural Analysis ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Lipid Lowering ◽  
Angelica Sinensis ◽  
Low Molecular Weight ◽  
Nonalcoholic Fatty Liver ◽  
Lipid Lowering Effect

scholarly journals Multidisciplinary Pharmacotherapeutic Options for Nonalcoholic Fatty Liver Disease

2012 ◽  
Vol 2012 ◽  
pp. 1-13 ◽  
Author(s):  
Kei Nakajima
Keyword(s):  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Lipid Lowering ◽  
Nonalcoholic Fatty Liver ◽  
Ras Blockers

Nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are multidisciplinary liver diseases that often accompany type 2 diabetes or metabolic syndrome, which are characterized by insulin resistance. Therefore, effective treatment of type 2 diabetes and metabolic syndrome should target not only the cardiometabolic abnormalities, but also the associated liver disorders. In the last decade, it has been shown that metformin, thiazolidinediones, vitamin E, ezetimibe, n-3 polyunsaturated fatty acids, renin-angiotensin system (RAS) blockers, and antiobesity drugs may improve hepatic pathophysiological disorders as well as clinical parameters. Accordingly, insulin sensitizers, antioxidative agents, Niemann-Pick C1-like 1 (NPC1L1) inhibitors, RAS blockers, and drugs that target the central nervous system may represent candidate pharmacotherapies for NAFLD and possibly NASH. However, the efficacy, safety, and tolerability of long-term treatment (potentially for many years) with these drugs have not been fully established. Furthermore, clinical trials have not comprehensively examined the efficacy of lipid-lowering drugs (i.e., statins, fibrates, and NPC1L1 inhibitors) for the treatment of NAFLD. Although clinical evidence for RAS blockers and incretin-based agents (GLP-1 analogs and dipeptidyl peptidase-4 inhibitors) is also lacking, these agents are promising in terms of their insulin-sensitizing and anti-inflammatory effects without causing weight gain.

scholarly journals Combined lipid-lowering therapy in patients with nonalcoholic fatty liver disease

Vrach ◽  
2018 ◽  
Vol 29 (11) ◽  
Author(s):  
P. Seliverstov ◽  
S. Sitkin ◽  
V. Radchenko ◽  
D. Tsurtsumia ◽  
S. Dzhadzhav
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Nonalcoholic Fatty Liver ◽  
Lowering Therapy

scholarly journals Severity of Nonalcoholic Fatty Liver Disease and Risk of Future Ischemic Stroke Events

Stroke ◽  
2021 ◽  
Vol 52 (1) ◽  
pp. 103-110
Author(s):  
Jie Xu ◽  
Liye Dai ◽  
Yijun Zhang ◽  
Anxin Wang ◽  
Hao Li ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Ischemic Stroke ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Lipid Lowering ◽  
Nonalcoholic Fatty Liver ◽  
Hazard Ratios ◽  
History Of

Background and Purpose: We assessed prospectively whether nonalcoholic fatty liver disease (NAFLD) and its severity predict future ischemic stroke (IS) events in a community-based cohort. Methods: From the Kailuan study, participants free of history of stroke, cancer, or myocardial infarction were enrolled after excluding alcohol abuse and other liver diseases. NAFLD was evaluated through ultrasonography. Participants with NAFLD were further stratified into mild, moderate, and severe groups. The outcome was the first occurrence of IS. The secondary outcomes included myocardial infarction and combined vascular events. We used Cox proportional hazards models to estimate hazard ratios and 95% CIs of incident IS according to presence and severity of NAFLD, adjusting for age, sex, physical activity, body mass index, smoker, history of hypertension, diabetes, hypercholesterolemia, lipid-lowering medication, HDL (high-density lipoprotein), triglyceride, hsCRP (high-sensitivity C-reactive protein), and fasting blood glucose. Results: During a median of 10.34 years of follow-up, we documented 3490 incident stroke cases among 79 905 participants. NAFLD was found in 24 874 (31.18%) participants. Relative to participants without NAFLD at the baseline, those with NAFLD had a 16% higher risk (95% CI, 1.07–1.26) of developing ischemic stroke, after adjusted for confounding variables. The hazard ratios for patients with mild, moderate, and severe NAFLD were 1.15 (95% CI, 1.05–1.25), 1.19 (95% CI, 1.06–1.34), and 1.21 (95% CI, 1.08–1.50), respectively. Conclusions: The severity of NAFLD is associated with a higher risk of future ischemic stroke events.

scholarly journals Influence of lipid-lowering decoction on biochemical indexes in rats with nonalcoholic fatty liver disease

2015 ◽  
Vol 23 (18) ◽  
pp. 2942
Author(s):  
Biao Tang ◽  
Meng-Jun Feng ◽  
Jia-Nan Xie ◽  
Yi-Xin Zhang ◽  
Zhou-Jin Tan ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Lipid Lowering ◽  
Nonalcoholic Fatty Liver
Sign in / Sign up

Export Citation Format

Share Document